Question 1

What are the potential side effects of pegylated interferon and ribavirin?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C clinical trial (NCT00100659). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for hepatitis C?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C clinical trial (NCT00100659). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like, and how often will we need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C clinical trial (NCT00100659). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any specific tests or procedures required during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C clinical trial (NCT00100659). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my child experiences side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C clinical trial (NCT00100659). Contact the study team or your healthcare provider for specific answers.

Question 6

How will participation in this trial affect my child's overall care plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C clinical trial (NCT00100659). Contact the study team or your healthcare provider for specific answers.

What this study is about